Rodman’s, Informedix hold introductory event for Med-eMonitor
ROCKVILLE, Md. InforMedix Holdings and Rodman’s Discount Drug Store have joined together to introduce the Med-eMonitor System that is used to monitor medication adherence and improved health for the drug store’s patients.
The Med-eMonitor System is an interactive so-called “Smart Pillbox” that not only stores medications, but also tracks patient adherence to the medication and health status. The system also uses alerts to tell people when they miss their medication or when their health declines.
The Rodman’s store located at 5100 Wisconsin Avenue, NW Washington, D.C., will host the event to introduce the system on Nov. 7.
“We are proud that Rodman’s, a pioneering independent pharmacy and household name in Washington for five decades, is the first pharmacy in the D.C. area to market the Med-eMonitor System,” said Bruce Kehr, chief executive officer and chairman of InforMedix and chairman of the board at the Institute on Aging at the University of Pennsylvania.
Haggerty appointed Mylan senior VP and global general counsel
PITTSBURGH, Pa. Mylan has announced that Joseph Haggerty has been appointed as senior vice president and global general counsel.
Haggerty will manage and oversee all legal issues and the provision of legal services, counsel and advice globally to all members of Mylan’s senior management, as global general counsel.
Haggerty joins Mylan from Sanofi-Aventis, where he served as vice president, general counsel, and corporate secretary.
“I am thrilled to be joining Mylan at this exciting time in the company’s history,” Haggerty said. “I look forward to joining the already impressive global management team and supporting them and their operations with my counsel as Mylan becomes one of the leading quality generic and specialty pharmaceutical companies in the world.”
Depomed and King terminate Glumetza agreement
MENLO PARK, Calif. and BRISTOL, Tenn. Depomed and King Pharmaceuticals have terminated their promotional agreement for Glumetza, a drug used to treat Type 2 diabetes.
Under the agreement, King has paid Depomed $30 million in termination and other fees. King will fulfill its promotion obligations through the end of 2007 and Depomed will not pay a promotion fee to King for the quarter ending on Dec. 31.
Carl A. Pelzel, president and chief executive officer of Depomed said that, “Our joint efforts in launching Glumetza have demonstrated the product’s value to patients and its commercial potential. Discussions with potential new marketing partners for Glumetza are already underway. We are confident that we can identify a partner that will assist us in continuing to drive growth in the primary care, endocrinology and other key healthcare markets. In the meantime, a portion of the proceeds from this termination agreement will be earmarked for the continued marketing and promotion of Glumetza.”